strative expenses for the fourth quarter of 2010 were $715,000, including $34,000 in share-based compensation, compared to $624,000, including $130,000 in share-based compensation, for the fourth quarter of 2009. The increase of approximately $91,000 in selling, general and administrative expenses was due primarily to additional costs of $30,000 related to the Company's internal sales force, increased director fees of $64,000, higher legal costs of $66,000 and an accounting adjustment of $26,000 that reduced expenses in 2009. These increases were partially offset by a decrease of $96,000 in share-based compensation.
For the year ended December 2010, selling, general and administrative expenses were $3.12 million, including $230,000 in share-based compensation, compared to $5.67 million, including $1.3 million of share-based compensation, for the same period in 2009.
The decrease of approximately $2,546,000 in selling, general and administrative expenses reflects reduced costs associated with our sales and marketing efforts of $1,182,000 due to lower head count and marketing expenses, a decrease of $1,167,000 in administrative compensation including share-based compensation, a decrease of $329,000 in legal fees as 2009 included expenses related to a proposed acquisition, lower consulting fees of $113,000, decreased legal fees related to our patents of $62,000 and lower travel expenses of $38,000.
These expense decreases were partially offset by an increase in director fees of $223,000, increased investor relation expenses of $73,000 and a commission of $30,000 related to the Aiqilin licensing agreement.
Other income and other expenses
For the year ended December 2010, interest and miscellaneous income was $10,000 as compared to $43,000 for the same period of 2009. The decrease of $33,000 is attributable to lower cash balances and interest yields during 2010.
Interest exPage: 1 2 3 4 5 6 7 Related medicine technology :1
. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update2
. ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®s Label Claim3
. ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex4
. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing5
. ULURU Inc. to Raise $500,000 in Registered Direct Offering6
. ULURU Inc. Reports Third Quarter 2010 Financial Results7
. ULURU Inc. Provides Altrazeal® Clinical Update8
. ULURU Inc. Announces Conference Call9
. ULURU Inc. Reports Second Quarter 2010 Financial Results10
. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference11
. ULURU Inc. Obtains Status of Approved Supplier With McKesson.